OBJECTIVE:To investigate the therapeutic effects of Jinxin oral liquid(金欣口服液,JX)on influenza A virus(H1N1)influenza virus infected mice.METHODS:We established a model of by intranasally infecting the mice with H1...OBJECTIVE:To investigate the therapeutic effects of Jinxin oral liquid(金欣口服液,JX)on influenza A virus(H1N1)influenza virus infected mice.METHODS:We established a model of by intranasally infecting the mice with H1N1 virus.The mice were then orally administered JX or ribavirin to evaluate their therapeutic effects in vivo.We conducted histologic and immunohistochemical analyses,enzyme linked immunosorbent assay or quantitative real-time polymerase chain reaction to assess lung damage and the expression of inflammatory cytokines.Western blot(WB)experiments was conducted to measure the activation of NOD-like receptor protein 3(NLRP3)pathway.Flow cytometry was employed to quantify the populations of alveolar macrophages(AMs).To block the NLRP3 pathway,mice were treated with MCC950.For AMs depletion,mice were intranasally administered a single dose of clodronate liposome.RESULTS:Administration of JX demonstrated a protective effect against H1N1-induced lung pathology by reducing lung injury,suppressing lung inflammation,and decreasing viral titer.JX significantly inhibited the production of pro-inflammatory cytokines,such as interleukin(IL)-1βand tumor necrosis factor-ɑ,in H1N1-infected mice.JX inhibits the activation of NOD-like receptor protein 3(NLRP3)/apoptosis-associated specklike protein containing a caspase recruitment domain/caspase 1 pathway in the lungs and AMs of H1N1-infected mice.The inhibitory effect of JX on IL-1βsecretion was mediated by blocking the NLRP3 pathway activation in AMs.CONCLUSIONS:These findings suggest that JX holds promise as a potential therapeutic agent for suppressing the aggressive pro-inflammatory response induced by H1N1 infection.Further research and development are warranted to explore the full potential of JX in the prevention and treatment of H1N1 infection。展开更多
目的:通过研究金欣口服液含药血清对呼吸道合胞病毒(RSV)活化诱导的Toll样受体3(TLR3)的干预作用,探讨其治疗RSV肺炎可能的免疫学机制。方法:RSV感染体外培养的RAW264.7细胞,采用金欣口服液含药血清进行干预,并设利巴韦林阳性对照,24h...目的:通过研究金欣口服液含药血清对呼吸道合胞病毒(RSV)活化诱导的Toll样受体3(TLR3)的干预作用,探讨其治疗RSV肺炎可能的免疫学机制。方法:RSV感染体外培养的RAW264.7细胞,采用金欣口服液含药血清进行干预,并设利巴韦林阳性对照,24h后收集细胞,Real time RT-PCR法测定TLR3 mRNA的表达变化;激光共聚焦显微镜观察免疫荧光细胞化学染色法处理的各组细胞TLR3表达水平;ELISA法检测各组细胞培养上清中白细胞介素-6(IL-6)含量,在核酸及蛋白水平探讨金欣口服液含药血清抗RSV感染的作用机制。结果:RSV感染RAW264.7细胞后24h,细胞中TLR3 mRNA和蛋白表达水平以及细胞培养上清中IL-6表达明显升高(P<0.01),而金欣组TLR3及IL-6表达均显著低于RSV感染组(P<0.01,P<0.05),且效果优于利巴韦林组(P<0.01,P<0.05)。结论:金欣口服液含药血清能下调RSV活化诱导的TLR3及其下游炎症因子IL-6的高表达,推测其为金欣口服液抗RSV感染的机制之一。展开更多
基金Young Elite Scientists Sponsorship Program by Chinese Association for Clinical Medicine(2021-QNRC2-B14)Colleges and universities in Jiangsu Province Natural Science Research:Investigating the Mechanism of Jinping Decoction Inhibiting the Differentiation of Myeloid-derived Suppressor Cells and Regulating Lipid Metabolism(22KJA360004)+3 种基金Jiangsu Graduate Practice Innovation Program:A Study on the Mechanism of Xiaofeng Xuanqiao Decoction in Treating Pediatric Rhinitis based on Interleukin-33/Suppression of Tumorigenicity 2(SJCX23_0803)Wuxi Health Commission Scientific Research Project:Observation on the Efficacy of Xiaofeng Xuanqiao Decoction in Treating Pediatric Rhinitis(WindPhlegm Obstructing Orifices Syndrome)and Its Influence on Serum IgE and Related Inflammatory Cytokine Levels(M202035)Project of High-level Construction of Key Traditional Chinese Medicine(TCM)Disciplines,China:Research on Tic Disorders from the Perspective of the Five Viscera Syndrome Treatment(NZYEK004)Project of Highlevel Construction of Key TCM Disciplines,China:Research on the Mechanism of Xiaofeng Xuanqiao Decoction in Treating Allergic Rhinitis based on the Interleukin-33/ST2 Axis(NZYEK006)。
文摘OBJECTIVE:To investigate the therapeutic effects of Jinxin oral liquid(金欣口服液,JX)on influenza A virus(H1N1)influenza virus infected mice.METHODS:We established a model of by intranasally infecting the mice with H1N1 virus.The mice were then orally administered JX or ribavirin to evaluate their therapeutic effects in vivo.We conducted histologic and immunohistochemical analyses,enzyme linked immunosorbent assay or quantitative real-time polymerase chain reaction to assess lung damage and the expression of inflammatory cytokines.Western blot(WB)experiments was conducted to measure the activation of NOD-like receptor protein 3(NLRP3)pathway.Flow cytometry was employed to quantify the populations of alveolar macrophages(AMs).To block the NLRP3 pathway,mice were treated with MCC950.For AMs depletion,mice were intranasally administered a single dose of clodronate liposome.RESULTS:Administration of JX demonstrated a protective effect against H1N1-induced lung pathology by reducing lung injury,suppressing lung inflammation,and decreasing viral titer.JX significantly inhibited the production of pro-inflammatory cytokines,such as interleukin(IL)-1βand tumor necrosis factor-ɑ,in H1N1-infected mice.JX inhibits the activation of NOD-like receptor protein 3(NLRP3)/apoptosis-associated specklike protein containing a caspase recruitment domain/caspase 1 pathway in the lungs and AMs of H1N1-infected mice.The inhibitory effect of JX on IL-1βsecretion was mediated by blocking the NLRP3 pathway activation in AMs.CONCLUSIONS:These findings suggest that JX holds promise as a potential therapeutic agent for suppressing the aggressive pro-inflammatory response induced by H1N1 infection.Further research and development are warranted to explore the full potential of JX in the prevention and treatment of H1N1 infection。
文摘目的:通过研究金欣口服液含药血清对呼吸道合胞病毒(RSV)活化诱导的Toll样受体3(TLR3)的干预作用,探讨其治疗RSV肺炎可能的免疫学机制。方法:RSV感染体外培养的RAW264.7细胞,采用金欣口服液含药血清进行干预,并设利巴韦林阳性对照,24h后收集细胞,Real time RT-PCR法测定TLR3 mRNA的表达变化;激光共聚焦显微镜观察免疫荧光细胞化学染色法处理的各组细胞TLR3表达水平;ELISA法检测各组细胞培养上清中白细胞介素-6(IL-6)含量,在核酸及蛋白水平探讨金欣口服液含药血清抗RSV感染的作用机制。结果:RSV感染RAW264.7细胞后24h,细胞中TLR3 mRNA和蛋白表达水平以及细胞培养上清中IL-6表达明显升高(P<0.01),而金欣组TLR3及IL-6表达均显著低于RSV感染组(P<0.01,P<0.05),且效果优于利巴韦林组(P<0.01,P<0.05)。结论:金欣口服液含药血清能下调RSV活化诱导的TLR3及其下游炎症因子IL-6的高表达,推测其为金欣口服液抗RSV感染的机制之一。
